Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$160.19 - $289.46
Previous CloseN/A
Volume86.50K
Average Volume (3M)931.39K
Market Cap
$17.22B
Enterprise Value$19.81B
Total Cash (Recent Filing)$118.34M
Total Debt (Recent Filing)$98.22M
Price to Earnings (P/E)42.4
Beta1.19
Next Earnings
May 08, 2025EPS Estimate
0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.79
Shares Outstanding70,226,105
10 Day Avg. Volume842,261
30 Day Avg. Volume931,386
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)N/A
Price to Sales (P/S)9.10
Price to Cash Flow (P/CF)31.90
P/FCF Ratio30.10
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.70
Enterprise Value/Ebitda44.69
Forecast
1Y Price Target
$326.07Price Target Upside32.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Insulet News
PremiumCompany Announcements
Insulet Closes $450 Million Senior Notes Issuance
PremiumCompany Announcements
Insulet Announces Pricing of $450 Million Senior Notes---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe RADIANT study showed a statistically significant benefit in patients using O5/Libre 2 compared to MDI, indicating superior outcomes for automated insulin delivery systems.
Market GrowthPositive outcomes from the RADIANT study may drive the adoption of O5/Libre 2 in the US, boosting the company's growth prospects.
Bears Say
Debt StrategyThe company has issued new senior unsecured notes at a higher interest rate to address existing convertible notes, which is part of a strategic financial restructuring.
Financial PerformanceThe new debt deal is slightly dilutive to EPS, reducing it by approximately 5%.
---
Ownership Overview
0.34% Insiders
41.77% Mutual Funds
27.70% Other Institutional Investors
4.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $160.19 and its highest was $289.46 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $17.22B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is May 08, 2025 which is in 30 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Feb 20, 2025. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.004 by $0.146.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 0.79.
How many shares outstanding does Insulet have?
Insulet has 70,226,105 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.15 in its last earnings report, beating expectations of $1.004. Following the earnings report the stock price went down -1.904%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
---
Insulet Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$326.07 (32.95% Upside)
$326.07 (32.95% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 248.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $139.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.23%
12-Months-Change
Fundamentals
Return on Equity
43.03%
Trailing 12-Months
Asset Growth
19.30%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
---
PODD Company Deck
---
PODD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in revenue and significant milestones for Omnipod 5, including expansion into the type 2 diabetes market and international markets. However, challenges such as a projected decline in the Drug Delivery segment and currency impacts on international revenue were noted.Read More>---
PODD Revenue Breakdown
74.73% U.S.
25.27% International
---
PODD Stock 12 Month Forecast
Average Price Target
$326.07
▲(32.95% Upside)
Technical Analysis
Best Analysts Covering PODD
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+24.35%
reiterated a buy rating last month
Copying Matthew Taylor's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +24.35% per trade.
---